Eryc™ capsules are a delayed release erythromycin (a macrolide antibiotic) produced by Mayne Pharma using proprietary pellet technology.
Indicated for the treatment of a wide variety of bacterial infections, Eryc™ erythromycin is formulated to protect erythromycin degrading in the acidic environment of the stomach, for optimal absorption in the intestine.
Eryc™ capsules are available in two dose strengths, 250mg and 333mg.
Eryc™ erythromycin capsules are currently licensed and sold in Australia, Canada, Sweden and the United Kingdom. Opportunities remain for licensing in a significant number of international territories.
Mayne Pharma offers Eryc™ capsules on the Pharmaceutical Benefits Scheme (PBS) in Australia.
This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.